Gent

• A Phase 1/2 Study of VX-522 in Subjects with Cystic Fibrosis Ended
  2023-504786-23-00 7 2024-11-18 Cystic Fibrosis
• A clinical study of MK-4646 in healthy people (MK-4646-002) Ended
  2024-516626-63-00 3 2024-11-18 HIV infection
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2024-511998-30-00 5 2024-10-18 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• Phase 2a, single center, randomized, double-blind, study to evaluate the immunogenicity and safety of one single administration of OVX836 in … Ended
  2024-516267-83-00 4 2024-10-15 Influenza
• A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended
  2024-516240-26-00 5 2024-10-11 Influenza
• Immunogenicity of licensed MF59 adjuvanted Influenza and SARS-CoV-2 vaccine combinations for Older Adults (ISOLDA) Ended
  2024-514798-23-00 4 2024-10-02 COVID-19 and flu
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511363-28-00 5 2024-09-24 hidradenitis suppurativa (HS)
• A clinical study of MK-5661 and placebo in healthy people (MK-5661-006) Ended
  2024-514980-25-00 3 2024-09-18 Pain
• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• Characterisation and intervention study in patients with long-term use of nasal decongestants. Ended
  2024-516312-25-00 6 2024-09-05 rhinitis medicamentosa
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera … Ended
  2023-505433-27-00 5 2024-08-13 Atopic Dermatitis
• A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec … Ended
  2023-508736-62-00 4 2024-08-08 Heart failure (HF) with reduced ejection fraction (HFrEF)
• A Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer Ended
  2022-502982-49-00 4 2024-07-15 Metastatic Castration-Resistant Prostate Cancer
• A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment … Ended
  2023-509738-20-00 6 2024-07-11 Plaque Psoriasis
• A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec … Ended
  2023-505086-83-00 4 2024-07-10 Tourette Syndrome
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0 … Ended
  2023-504378-39-00 1 2024-06-26 Influenza
• MK-4646 Single Ascending Dose Study and DDI in Healthy Participants Ended
  2024-510899-20-00 1 2024-06-19 HIV infection
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Phase I, randomized, double-blind, multi-centre, placebo-controlled, dose-escalation study to evaluate the safety, reactogenicity and immu … Ended
  2024-511194-29-00 1 2024-06-16 Yellow fever
• A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin … Ended
  2023-510196-59-00 5 2024-06-15 Respiratory Syncytial Virus Infections

Showing 721–744 of 904 trials